EC authorizes Pfizer’s PREVENAR 20 vaccine for pediatric Use
In a landmark decision, Pfizer Inc. (NYSE: PFE) has been granted marketing authorization by the European Commission (EC) for its 20-valent pneumococcal conjugate vaccine, PREVENAR 20, aimed at combating invasive pneumococcal disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae in infants, children, and adolescents aged between 6 weeks and less than 18 years. […]